Who
Carole Ben-Maimon
President and CEO
Company insider
Files Form 4 as: President and CEO, Larimar Therapeutics; Director, Teligent; President, Global Pharm., Impax Laboratories.
In numbers
- Trades disclosed
- 45
- Buys
- 4
- Sells
- 0
- Bought
- $142K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 28 Oct 2011
- Last trade
- 26 Jan 2026
- Last filed
- 27 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,100 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,600 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,600 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,100 at $0.00 | filing |
| 22 Jan 2025filed 24 Jan 2025 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —546,000 at $0.00 | filing |
| 22 Jan 2025filed 24 Jan 2025 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —396,750 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —66,125 at $0.00 | filing |
| 17 May 2023filed 18 May 2023 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K5,000 at $3.71 | filing |
| 31 Jan 2023filed 2 Feb 2023 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —205,000 at $0.00 | filing |
| 16 Sep 2022filed 19 Sep 2022 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K31,746 at $3.15 | filing |
| 10 May 2022filed 12 May 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —182,000 at $0.00 | filing |
| 21 Jul 2021filed 22 Jul 2021 | Teligentoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 19 Jan 2021filed 21 Jan 2021 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —106,700 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | Teligentoption or derivative | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 29 Sep 2020filed 30 Sep 2020 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —411,400 at $0.00 | filing |
| 26 Jun 2020filed 30 Jun 2020 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code J | —25,083 at $0.00 | filing |
| 2 Jan 2020filed 3 Jan 2020 | Teligentoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.